Autoimmune biotech Landos Biopharma files for a $100 million IPO

Landos Biopharma, a Phase 2 biotech developing oral small molecule therapies for autoimmune diseases, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. The company leverages its proprietary AI-based precision medicine LANCE platform to id

source https://www.nasdaq.com/articles/autoimmune-biotech-landos-biopharma-files-for-a-%24100-million-ipo-2021-01-13

Total Pageviews

ACTIVE:

PyndanEX - Allocated Industries

Endeavor To Where It Matters! | Economic Calendar by TradingView

ΛPP.IPΛI 🏄 Powered by Surfing Waves!